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In normal prostate, neuroendocrine (NE) cells are rare and interspersed among the epithe-
lium.These cells are believed to provide trophic signals to epithelial cell populations through
the secretion of an abundance of neuropeptides that can diffuse to influence surrounding
cells. In the setting of prostate cancer (PC), NE cells can also stimulate surrounding prostate
adenocarcinoma cell growth, but in some cases adenocarcinoma cells themselves acquire
NE characteristics.This epithelial plasticity is associated with decreased androgen receptor
(AR) signaling and the accumulation of neuronal and stem cell characteristics. Transfor-
mation to an NE phenotype is one proposed mechanism of resistance to contemporary
AR-targeted treatments, is associated with poor prognosis, and thought to represent up
to 25% of lethal PCs. Importantly, the advent of high-throughput technologies has started
to provide clues for understanding the complex molecular profiles of tumors exhibiting
NE differentiation. Here, we discuss these recent advances, the multifaceted manner by
which an NE-like state may arise during the different stages of disease progression, and
the potential benefit of this knowledge for the management of patients with advanced PC.
Keywords: prostate cancer, neuroendocrine differentiation, small-cell carcinoma, cancer biology, NRSF/REST,
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INTRODUCTION
Prostate cancer (PC) is the most frequently diagnosed malignancy
in men and is accompanied by a frequent source of morbidity
and mortality (1). The vast majority of prostate tumors appear in
the form of adenocarcinoma, a type of tumor assumed to derive
from transformation of the glandular cells of the prostate. Like
the normal prostatic glands that develop, regenerate, and func-
tion under the influence of androgens, prostatic adenocarcinoma
(thereafter adeno-PC) also relies on androgens working through
the androgen receptor (AR) for its development and progres-
sion. This is the basis for the use of therapeutic intervention to
block androgen synthesis (e.g., chemical and surgical castration),
or inhibit AR function (e.g., AR antagonists), as standard therapies
for patients with advanced and recurrent diseases (2, 3). Although
these treatments provide for most patients clinical responses and
symptomatic relief, explained partly by an effective blockade of
proliferation and induction of cell death in a proportion of PC
cells, they rarely eradicate all PC cell populations, and ultimately
most patients develop resistance to these treatments as well as an
almost uniformly fatal development. For many scientists and clin-
icians, the manifestation of “neuroendocrine differentiation” or a
“neuroendocrine phenotype” is associated with progression of PC
to castrate-resistant disease generally representing late-stage and
lethal events in prostate tumorigenesis. However, these generic
terms assume many different aspects and components during
natural or treatment history of PC that are not completely under-
stood due to lack of knowledge of the underlying biology. The
intent of this review is to present our current knowledge about the
multifaceted forms that can take neuroendocrine (NE) differen-
tiation in PC and describe recent advances in our understanding
of the molecular perturbations that might control or drive the NE
phenotype in this disease.
NEUROENDOCRINE CELLS OF THE HUMAN PROSTATE
Neuroendocrine cells are found in many tissue types including
normal prostate. The prostate is a male accessory sex gland that
functions to produce a major fraction of seminal fluid. In nor-
mal prostatic parenchyma, the NE cells are generally rare and
widely interspersed amongst the epithelial basal and luminal cells
grouped within glandular structures called prostatic acini and
ducts (4). As part of a diffuse NE system, prostatic NE cells secrete
many types of neuropeptides (including bombesin, calcitonin,
parathyroid-like hormone, serotonin, and adrenomedullin) and
growth factors (including VEGF) that are believed to maintain
homeostasis of the surrounding epithelial cell populations (5). In
the cancer setting, they can persist, and their secretory products
may influence surrounding PC cells by acting on their rates of
cell death and/or proliferation (5–7). Prostatic NE cells present
with dendritic processes comparable to that found in neuronal
cells and express a variety of NE markers (including chromo-
granins, synaptophysin, and CD56). These cells may derive from
the differentiation of progenitors located in the basal cell layer.
As terminally differentiated cells, they are devoid of proliferative
activity and usually express anti-apoptotic factors such as survivin
(8). Further research is needed to decrypt the role of normal NE
cells in the physiopathology of PC. Intriguingly, their number may
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vary depending upon the ethnic backgrounds. They are found at
a relatively low rate in African-American men, a population more
likely to develop PC, which supports a protective role for this cell
type in prostate carcinogenesis (9).
DE NOVO NEUROENDOCRINE PROSTATE TUMORS
An extremely small proportion of PC patients present with overt
“de novo” NE tumors in that these tumors are composed of NE
tumor cells and diagnosed outside the context of a previously
known adeno-PC. Immunohistochemical examination usually
shows negativity for AR as well as for prostate specific antigen
(PSA), and positivity for NE markers with varied levels. NE tumors
include small-cell carcinoma of the prostate (SCPC) (<0.1% of all
diagnosed PCs) (10) as well as exceptionally rare tumors such as
large cell NE carcinoma (a few cases worldwide) (11), and low-
grade carcinoid, comparable to carcinoid in other locations (12).
These tumors can be pure or admixed with prostatic adenocarci-
nomas. An atypical situation has been described in one case of a
so-called “hybrid” tumor presenting with both NE and epithelial
phenotypes (13).
Small-cell carcinoma of the prostate has been described by
numerous investigators and is defined as a poorly differentiated
NE cancer microscopically identical to its most common coun-
terpart in the lung, small-cell lung carcinoma (14, 15). Unlike the
scattered NE cells in normal or benign prostate, the NE tumor
cells in SCPC are highly proliferative, metastatic, and resistant to
most conventional therapies. As a result, SCPC is invariably fatal
with most patients dying within 2 years of diagnosis despite very
aggressive chemotherapeutic regimens (16–18). To date, the ori-
gin of these tumors remains uncertain. They can share similarities
with basal/progenitor cells (P63+, c-Kit+) (19). This has led to the
speculation that they derive from transformation of multipoten-
tial prostatic progenitors. Other studies performed in genetically
engineered mouse models have suggested the transformation of
normal prostatic NE cells as origin of these tumors (20). Finally, as
will be repeatedly reiterated in this review, ample evidence pleads
in favor of the transformation of adenocarcinoma.
NEUROENDOCRINE DIFFERENTIATION IN UNTREATED
PROSTATE ADENOCARCINOMA
Hormonally untreated adeno-PCs, sometimes referred to as “hor-
mone naïve” adeno-PCs, also contain isolated cells staining posi-
tive for NE markers. In most cases, these cells are present in smaller
numbers compared with that in normal or benign prostate. How-
ever, in 5–10% of adeno-PCs, these cells are found in greater
numbers in the form of solitary cells, or aggregates of densely
packed cell clusters (<50 cells). This pattern is designated as focal
NE differentiation and the adenocarcinoma contingent remains
predominant in such setting. Moreover, these cells are usually
referred to as “NE-like” cells as they do not necessarily resem-
ble normal NE cells but rather show the same appearance as
adenocarcinoma cells (21). Importantly, genetics characterization
of laser captured microdissected cells from pathological speci-
mens has demonstrated that these NE-like cells are malignant
cells linked genetically to the neighboring adenocarcinoma cells
(22). This knowledge, also supported by number of experimen-
tal data generated in vitro and in rodents, led to the notion that
prostate adenocarcinoma cells have the capacity to transdifferen-
tiate to acquire a more NE phenotype through a process termed
NE transdifferentiation. It has been suggested to play a role in
sustaining prostate tumor growth and progression (23, 24). Yet,
controversy arises especially when interrogating for prognostic
utility of assessing for NE markers in tissues or in blood (25,
26). Other clinical studies have found that pretreatment NE dif-
ferentiation may have prognostic utility in subgroups of patients
being treated for advanced disease. In a population of patients who
received radiotherapy as a primary treatment, the presence of NE
differentiation involving>1% of tumor cells on initial PC biopsies
has been associated with an increased risk of distant metastasis and
reduced cancer-specific survival time (27, 28). Evaluation of inde-
pendent patient cohorts may be needed to determine the veracity
of these new findings.
On the other hand, it is well-accepted that cultured PC cells
can be directly induced to undergo an NE transdifferentiation
process in vitro by exposure to a wide spectrum of stimuli. This
phenotypic switch has been seen especially in cultures of the PC
cell line LNCaP, and occasionally in cultured PC3 and DU145
cell lines, when cells are grown in medium supplemented with
dibutyryl-cyclic AMP (db-cAMP) (29), forskolin, cytokines (e.g.,
IL6), growth factors (e.g., EGF, HB-EGF), or in hormone-depleted
medium (30). This topic has been extensively covered by two
reviews to which the reader is referred (31, 32). It is important
to consider that some of these factors may be components of the
tumor microenvironment in some patients prior to any therapeu-
tic intervention. However, this focal NE differentiation appeared
to be relatively uncommon in prostate tumors of patients who
did not receive any systemic therapy, and hence, NE transdiffer-
entiation is becoming increasingly recognized as an adaptation
mechanism allowing PC cell populations to adapt a wide spectrum
of therapeutic agents (33–36).
NEUROENDOCRINE DIFFERENTIATION IN HORMONALLY
TREATED AND CASTRATE-RESISTANT PROSTATE CANCERS
There seems to be a consensus, among PC researchers, to say that
transdifferentiation from an epithelial-like phenotype to an NE-
like phenotype represents a noteworthy biological process that can
be considered a consequence of the selective pressure induced by all
treatments that lead to a fall in androgen levels, or to blocking the
action of these steroid hormones. Ralph Buttyan and co-workers
were the first to observe that in LNCaP cells, which is by far
the most commonly used model in PC research (37), the cells
undergo an NE transdifferentiation, when chronically exposed to
medium lacking androgens and that restoring androgens back to
the medium suppressed this NE transdifferentiation state (30).
Many laboratories have confirmed this finding, as well as show-
ing that in most instances the transdifferentiation implicates a
reduced activity and/or expression of AR (38). Additionally, there
have been reports in clinical literature that focal NE differentiation
is increased within castrate-resistant PC (CRPC) tumors as well
as levels of NE-derived peptides such as neuron-specific enolase
(NSE) and chromogranin-A in the serum of CRPC patients (26,
39, 40). In patient specimens, this is usually reflected by an increase
in the size and number of overt NE-like clusters (36, 39, 41).
These reports also showed that the increased presence of the NE
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component can manifest a few months following implementation
of androgen deprivation therapy, which may be months or even
years before the diagnosis of castrate resistance. This data coupled
with clinical observation that adenocarcinoma cells present in the
prostate are generally slowly proliferating (42), again support the
idea that NE-like tumor cells have transdifferentiated from adeno-
carcinoma in response to treatment. One important question has
remained unsolved: does these coexisting tumor variants interact
with each other“in vivo”as a means for progression? First attempts
to address this question indicate this might be the case (43, 44).
Additional studies are needed to validate this hypothesis.
Moreover, one must consider the possible metaplastic nature of
NE-like tumor cells. In this respect, some evidence already denotes
that NE differentiation may take various forms during tumor pro-
gression with NE-like tumor cells exhibiting diverse NE traits,
sometimes with loss or gain expression of certain NE markers (36,
38, 41, 45, 46). NE transdifferentiation may be partial, incomplete,
or even reversible. A similar situation applies with other types of
transdifferentiation processes (EMT or MET for example) (47).
Thus, we posit that under prolonged hormonal manipulations,
multiple NE-like tumor cell populations, or NE subtypes (from
well to poorly differentiated), be selected within cancers of var-
ied proliferative activity, expressing various levels of NE markers
and/or more epithelial markers. In tumors having progressed to a
therapeutic resistance, NE state may transiently disappear to reap-
pear later on with subsequent treatments administered including
anti-AR or chemotherapy regimens.
Importantly, a substantial proportion of heavily treated CRPC
shows many of the salient features of de novo small-cell carcino-
mas, admixed or not with adenocarcinoma. It is currently difficult
to assess the prevalence of such SCPC disease because metasta-
tic CRPC patients are not routinely biopsied in end-stage disease.
Nevertheless, it is estimated that at least 25% of patients with
advanced PC may eventually develop this type of highly aggressive
NEPC (48). In some cases, SCPC not only coexists with an ade-
nocarcinoma component, but also shares genetic alterations such
as TMPRSS2–ERG gene fusion (49–51) that are thought to arise
specifically from prostatic adenocarcinoma cells responding to
androgens (52, 53). This again is evocative of a transdifferentiation
model to explain the emergence of this NEPC type. Alternatively,
this could indicate that small-cell carcinoma and adenocarcinoma
components may arise from a tumor clone with stem-like proper-
ties that gave rise to at least two distinct components (i.e., epithelial
and NE), which were able to persist and evolve in parallel during
tumor progression. In cases of clinically suspected SCPC progres-
sion, patients are often treated with platinum-based chemotherapy
with regimens similar to small-cell lung cancer (54, 55). However,
despite initial responses, most patients progress rapidly and there
is no standard second line therapy.
We and others are concerned that with the introduction of
novel potent AR-targeted drugs into the clinic for CRPC, the
incidence of SCPC transformation may increase (48). Future
investigations should address these questions, but not restrict
the analysis to anti-AR targets. We already know that cultures
of androgen-independent LNCaP derivatives, apparently refrac-
tory to NE transdifferentiation caused by an androgen impov-
erished environment, can regain numerous NE attributes under
chronic exposure to docetaxel (36), the standard-of-care first-line
chemotherapy for CRPC patients. Whether such finding can be
transferred to patients or any other preclinical models has yet
to be documented. Additionally, several pieces of evidence sug-
gest that ionizing radiation induces NE transdifferentiation of
LNCaP cells with the acquisition of cross-resistance to radiother-
apy, chemotherapy, and hormonal therapy (33). It will be impor-
tant to further investigate this intriguing possibility in clinical
studies, especially because many PCa patients receive radiother-
apy either as a primary therapy, salvage therapy, or in combination
with surgery or hormonal therapy (56, 57). Of note, Komiya and
colleagues have recently reported a case of SCPC, which developed
after high-dose-rate brachytherapy (58).
These instances illustrate the complexity of the molecular
events that govern NE differentiation and support the need to
identify novel molecular components and markers that may assist
in deciphering NE transdifferentiation process and better clas-
sify the different grades of NE differentiation as well as their
significance.
TOWARD MOLECULAR UNDERSTANDING OF WHAT DRIVES
NEUROENDOCRINE PHENOTYPE IN PROSTATE CANCER
The underlying biology of NEPC has remained a conundrum for
scientists and clinicians alike. A better understanding of the mole-
cular events underlying NEPC transformation is urgently needed
to provide therapeutic solution in the management of PC patients
with lethal diseases. The recent discovery of some of the molecu-
lar components and genetic alterations driving the NE phenotype
in PC takes up an important step closer to this goal. Using next-
generation sequencing as a tool to define the transcriptome of
both NE- and adeno-PCs, we discovered that the vast major-
ity of NEPC over-express the cell cycle kinase AURKA (Aurora
kinase A) and MYCN compared to adenocarcinoma (50). These
two proto-oncogenes cooperate to drive a malignant phenotype
similar to other N-myc driven tumors (59). Gene amplification
could explain the high-level expression of these genes in most
instances. Moreover, these two proto-oncogenes seem to work in
synergy to drive aggressiveness and NE phenotype in PC. Perhaps
more importantly, in this study we provided preclinical evidence
that inhibition of Aurora kinase using PHA-739358 treatment
effectively impeded the growth of NE tumor cells in vitro and
in vivo. This observation stimulated the implementation of a clin-
ical trial that will evaluate the effectiveness of a second-generation
inhibitor of Aurora kinase A in patients with metastatic PCa
with confirmed NE phenotype, or strong suspicion of NE dis-
ease (metastatic development in the absence of PSA progression)
(ClinicalTrials.gov; identifier: NCT01799278).
Notably, in our original study it was also possible to detect
AURKA over-expression and amplification in a few primary
adeno-PC cases, at least in a small fraction of neoplastic cells (50).
An important follow-up question has been to determine if adeno-
PC cases harboring AURKA and/or MYCN alterations are more
likely to transform into aggressive NEPC. To address this point, we
have inspected for AURKA and MYCN alterations in tissue spec-
imens from selected patients having developed NEPC along the
course of their disease, comparing it to an unselected series with
no apparent history of NE-related disease (60). This retrospective
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assessment showed thatAURKA and MYCN amplifications in pri-
mary adeno-PC effectively predict for a late-stage development of
NEPC in CRPC patients also suggesting these molecular alter-
ations may predispose for development of the small-cell disease
from adeno-PC.
Recent surveys suggest that RB loss (61–63) and MYC over-
expression underlie the development of NEPC lesions (16, 64).
Perturbations of the tumor microenvironment, including hypoxic
conditions also appeared to play a role in the emergence of an NE
phenotype (65, 66). In 2010, Ronai and his colleagues reported on
the potential role of a hypoxia-mediated “FoxA2/HIF-1a” com-
plex in driving NE phenotype in mouse prostate tumors, which
is concordant with previous studies pointing out the preferen-
tial occurrence of FOXA2 expression in human NEPC (67). If
confirmed, these results could provide a biologic rationale for fur-
ther assessment of targeting these components to prevent NEPC
development.
Another significant breakthrough came from the study of
Lapuk et al. with the discovery of REST downregulation in associa-
tion with the prevalence of NE phenotype in PCa (68). It is relevant
to note here that a recent survey suggests that hypoxia induces miR-
106b, miR-93, and miR-25, which may in turn down-regulated
REST in PC cells (69). REST namely RE1-silencing transcription
factor [also known as neuron-restrictive silencer factor (NRSF)]
was identified in 1995 as a master repressor of the neuron-specific
acting genes during neurogenesis but it very rapidly emerged that
REST plays a broader role than originally anticipated (70, 71). In
LNCaP cells, REST depletion resulted in upregulation of several
NE markers (68). In their 2013 study, Svensson et al. confirmed
this information and revealed novel molecular paradigms link-
ing the androgen/AR axis, REST, and NE differentiation (72). Also
intriguing was the discovery of an invert correlation between REST
and the protocadherin (PCDH) genes PCDH11Y and PCDH11X.
Protocadherins constitute the largest subfamily of cadherins in
the genome. PCDH genes are overwhelmingly expressed in neu-
ronal cells of the central and peripheral nervous systems where
they perform important functions for formation, maintenance,
and integrity of neural circuitry (73). Recently, they have received
increased attention for their roles in cancer (74). PCDH11Y gene
products are highly upregulated in hormonally treated and CRPC
tumors and so are also commonly referred to as PCDH–PC (36,
75). In collaboration with Dr. Buttyan and his colleagues, we have
shown that over-expression of PCDH–PC in human prostate ade-
nocarcinoma cells promotes NE transdifferentiation and this is
further supported by our survey of human specimens (36, 76).
The human and male specific nature of this PCDH is particu-
larly intriguing in the context of PC, a malignant disease that
is mainly restricted to humans. PCDH11Y/PCDH–PC gene lies
within human Y chromosome at Yp11.2 (77, 78). This genomic
region was acquired during evolution from primates to humans
from duplication–transposition of an X chromosome region [con-
tainingPCDH11X (Xq21.3)] onto theY chromosome (79,80). The
latter likely evolved and acquired a few sequence changes that sig-
nificantly altered translation products diverging functionally from
those of PCDH11X products (77,78,80). To our surprise,Svensson
et al. did not report on deregulation of other PCDH members fol-
lowing perturbation of REST expression, while previous surveys in
vertebrates point to a universal role of REST in regulation of PCDH
genes (81, 82). This argues for exclusive regulatory events in place
in PC cells. Interestingly, the transcriptomic data obtained also
indicate that REST not only acts to repress neuronal genes but also
genes involved in cell cycle progression, includingAURKA. Follow-
up studies should help get better insight into this regulation.
Another important aim will be to explore further if perturba-
tions of REST in PC cells can regulate other PCDH members with
potential effect in directing the NE phenotype.
INTEGRATING NEUROENDOCRINE DIFFERENTIATION IN THE
CONTEXT OF HETEROGENEITY AND PLASTICITY OF
PROSTATE CANCER
Despite significant advances in the identification of stimuli and
molecular events presumably governing NE differentiation, it is a
utopia to think that these events take place in all PC cells. This
is illustrated by the observation that under some circumstances,
over-expression of PCDHY /PCDH–PC seems capable of support-
ing tumor cell growth and resistance to cell death without any
marked increase or association with NE differentiation (36, 75,
78). In vitro, PCDH–PC over-expression induces NE transdiffer-
entiation of the LNCaP cells through a Wnt signaling-dependent
mechanism, but in cell lines with a different genetic background,
PCDH–PC appears to stimulate this pathway without apparent
effects on the NE phenotype (published and non-published data).
Whereas subsequent studies have substantiated the link between
Wnt activation and NE differentiation in various PC models (83,
84), other studies have found Wnt activation as being associated
with self-renewal (85), oncogenesis, and castration resistance (86,
87). These disparate effects can be explained by clonal-dependent
response of cells for a given signal. In fact, there is no doubt that
NE differentiation and NE transdifferentiation, like for many other
biological processes, are largely influenced by the origin of the
cells as well as by clonal oncogenic events probably emerging dur-
ing tumor development. It is well-established that aberrant Wnt
signaling is involved in various malignancies and that Wnt signal-
ing is also important for differentiation and normal development,
including neural development (88, 89).
Like Wnt signaling, REST appears to possess different activities
in various tumor or cellular contexts (90). REST expression may
have pro-oncogenic activity in nervous tumors and is found con-
sistently upregulated in neuroblastomas and medulloblastomas
(91, 92), while in small-cell lung carcinomas, loss of REST activ-
ity is observed and related to NE phenotype (93). In neural
stem/progenitor cells, REST can cooperate with other molecu-
lar alterations including MYC over-expression to induce tumor
formation in the cerebellum by blocking neuronal differentia-
tion and maintaining the “stemness” of these cells (94). Little is
known about how developmental signaling pathways influence
REST function. This is an area in which more research is needed.
In the case of PC, investigators will have to deal with the mul-
tiple nodes through which these pathways (e.g., Wnt, hedgehog,
and Notch) can influence AR signaling at the different stages of
PC progression (66, 95–98). Androgen/AR axis exerts a protective
effect toward REST in adeno-PC (72). Since aberrant Wnt signal-
ing can modulate AR signaling at multiple levels and trigger NE
transdifferentiation, it is tempting to speculate that Wnt signaling
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FIGURE 1 | Schematic model for the emergence of NE phenotype in
tumor progression in prostate cancer. An NE-like or NE phenotype may
be driven by a conjunction of molecular events and environmental changes,
combined with natural selection. Owing to treatment intervention and/or
certain environmental changes associated with tumor development, some
adenocarcinoma cells having accumulated genetic alterations are able to
transdifferentiate from epithelial-like to neuroendocrine-like tumor cells that
have superior anti-apoptotic and therapeutic-resistant properties. In
addition, neuropeptides and growth factors released by the
NE-transdifferentiated cells may act either as autocrine or paracrine signals
to promote survival and tumor progression of both NE and adenocarcinoma
components. Accumulation of new genetic alterations such as RB loss,
AURKA, and MYCN amplifications under evolutionary pressures, or through
natural selection of preexisting NE-like tumor subpopulations, may promote
rapid cell expansion and subsequent emergence of a predominant NE
component in the form of small-cell carcinoma characterized by rapid
proliferative activity. Alternatively, small-cell carcinoma could arise by direct
transformation of adenocarcinoma. Adenocarcinoma and small-cell
carcinoma components may also originate from a common tumor clone
with stem-like properties, or a cancer stem cell, converted into more
differentiated tumor cells that accumulated molecular alterations driving
epithelial or NE phenotypes. To date, very limited amounts of data are
supportive of normal prostatic NE cell as a cell of origin for NE tumors (not
shown here).
also plays some role (direct or indirect) in REST regulation. Of
further interest, there are reasons to believe that canonical Wnt
pathway directly regulates the expression of REST (99), and that
REST cross-talks with hedgehog signaling (100). In this line, Wnt
and Hedgehog pathways have been implicated in pulmonary and
extra-pulmonary small-cell carcinomas (101–103). Furthermore,
FOXA2 gene, a gene critically involved in NEPC tumors (65, 67),
is a direct target of hedgehog signaling (104) and is induced by
active Wnt signaling (105).
One pending question concerns the molecular similarities and
differences between focal NE differentiation found in adeno-PC
and extensive NE differentiation that dominates in SCPC, coex-
isting or not with adeno-PC. To what extent these are helpful to
support or refute the process of NE transdifferentiation as origin
of NEPC? As we now understand it, REST is essential in controlling
NE phenotype of both SCPC and focal NE in adeno-PC. Poten-
tially modulated by a long list of factors, it can be considered as
a universal regulator of NE phenotype. However, the prolifera-
tive activity of NE tumor cells of SCPC generally contrasts with
that observed in adeno-PC even when assessment is performed at
advanced stage (106). Although the proliferation rate of adeno-
PC certainly increases in the metastatic setting, adeno-PC is still
considered as a slow progressing tumor type (42), and it seems
likely that tumor cells confined into NE-like clusters are likewise
slow-growing or quiescent (Figure 1). Nonetheless, in that sit-
uation, the peptide hormones produced by NE-like tumor cells
may be feeding adjacent and even distant adenocarcinoma cells.
Whether these adenocarcinoma cells are truly addicted to the NE
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component for their relatively “slow” but “persistent” growth is a
matter of future investigations.
As noted above, genetic alterations such as MYCN and AURKA
amplifications or RB depletion are considerably enriched in SCPC
(50, 63). These alterations may be the manifestation of commit-
ment through an uncontrolled proliferative state coinciding with
the rapid tumor progression of this form of NEPC (Figure 1).
Additional relevant alterations include MYC amplification, TP53
mutation, or PTEN reduction, which are found in both SCPC
and adeno-PC principally in late-stage disease (63, 107). Impor-
tantly, each of these events has the potential to sustain PC cell
growth in androgen-deprived or AR-inactivated conditions (108–
111). This is consistent with the seeming AR-independent nature
of most if not all SCPC. Thus, although the direct role of these
genetic perturbations in driving an NE phenotype is far from
being established, it remains that they may participate in con-
trolling proliferative activity and survival of SCPC. Likewise, if we
assume that some of these molecular events occur in at least a
fraction of quiescent NE-like tumor cells confined to adeno-PC, it
is then easy to foresee how the proliferative activity will increase in
these cells, and hence, facilitate expansion of the NE component
in adeno-PC, that perhaps will become the predominant pattern
in an AR-independent context (Figure 1). Further studies will
be necessary to elucidate the precise molecular networks engaged
downstream of these alterations in the different NE populations.
The current development of single-cell purification techniques
coupled with high-throughput analyses should provide valuable
information toward this goal.
CONCLUSION
Neuroendocrine cell-like tumor cells as well as pure NE tumor
cells are present at all stages of prostate tumor development. Rarely
predominant de novo, NE components are especially enriched in
the late stages of the disease coincident with metastatic spread
and treatment resistance. This NE enrichment may be explained
by transdifferentiation of preexisting adenocarcinoma cells or the
derivation of clones with stem-like properties differentiating into
various phenotypes (Figure 1). In one way or the other, these
two processes are preferentially mobilized under persistent treat-
ments in conjunction with appearance of genetic perturbations
initiating or maintaining an NE phenotype. The pattern of these
molecular events may also explain why most NE-like tumor cells
in adeno-PC remain quiescent when the vast majority of NE
tumor cells in SCPC are rapidly cycling. On the other hand, the
early occurrence of these events in adeno-PC could presage the
emergence of SCPC from adeno-PC. In a sense, PC represents
a unique situation among other malignancies in which the NE
system is progressively mimicked by cancer cells and eventually
corrupted so as to adapt and progress through treatments. While
therapeutic strategies have focused on attempting to block the
androgen/AR axis, targeting the NE component has the poten-
tial to provide new therapeutic solution in the management of
PC patients with painful and lethal disease. Research and clinical
studies are now underway to improve treatment modalities and
test new agents that hold great promise in treating patients with
this condition.
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